Fairfield Financial Advisors LTD Sells 18,909 Shares of Novo Nordisk A/S $NVO

Fairfield Financial Advisors LTD decreased its stake in shares of Novo Nordisk A/S (NYSE:NVO) by 62.3% during the third quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 11,449 shares of the company’s stock after selling 18,909 shares during the period. Fairfield Financial Advisors LTD’s holdings in Novo Nordisk A/S were worth $635,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors also recently modified their holdings of the company. True Wealth Design LLC lifted its holdings in Novo Nordisk A/S by 209.8% in the third quarter. True Wealth Design LLC now owns 443 shares of the company’s stock worth $25,000 after buying an additional 300 shares during the period. NewSquare Capital LLC raised its position in shares of Novo Nordisk A/S by 174.1% in the 2nd quarter. NewSquare Capital LLC now owns 444 shares of the company’s stock worth $31,000 after acquiring an additional 282 shares in the last quarter. Mid American Wealth Advisory Group Inc. purchased a new position in shares of Novo Nordisk A/S in the 2nd quarter valued at approximately $37,000. Maseco LLP bought a new stake in shares of Novo Nordisk A/S during the second quarter valued at approximately $39,000. Finally, Steigerwald Gordon & Koch Inc. purchased a new stake in Novo Nordisk A/S in the third quarter worth $39,000. Hedge funds and other institutional investors own 11.54% of the company’s stock.

Key Stories Impacting Novo Nordisk A/S

Here are the key news stories impacting Novo Nordisk A/S this week:

• Positive Sentiment: Amazon Pharmacy began offering Novo Nordisk’s new Wegovy pill through insurance plans and a cash-pay option, expanding U.S. distribution and making the first-ever oral GLP‑1 from Novo more accessible to patients — a direct demand and revenue catalyst. Amazon Pharmacy offers Novo Nordisk’s Wegovy pill
• Positive Sentiment: Major retail pharmacy availability reported by CNBC/MSN increases distribution visibility and could shorten the time to volume adoption for the Wegovy pill, supporting revenue upside versus slower clinic-based rollouts. Amazon Pharmacy starts offering Novo Nordisk’s Wegovy weight-loss pill
• Positive Sentiment: Investor research pieces flag Novo as a top pick for 2026 and highlight the FDA‑approved Wegovy pill as a growth catalyst; analysts note robust margins and free cash flow potential (but also cite pricing and competition risks). This supportive analyst tone can lift sentiment and trading interest. Novo Nordisk: A Pill For Growth
• Neutral Sentiment: The JPMorgan Healthcare Conference will put pharma pipeline updates and potential M&A back in focus; Novo may benefit from heightened investor attention but concrete impacts depend on announcements made at the event. Healthy Returns: What to expect from pharma at the JPM conference
• Neutral Sentiment: Marketing and PR activities — e.g., a public conversation on weight stigma at a major NYC commuter hub — help brand and patient engagement but are unlikely to move near-term revenue materially. Novo Nordisk conducts a new conversation on weight stigma at major NYC commuter hub
• Neutral Sentiment: Recent price commentary (Zacks note on a modest prior-day gain) reflects momentum but is informational rather than a fundamental driver. Novo Nordisk (NVO) Surpasses Market Returns

Analyst Upgrades and Downgrades

A number of brokerages have recently commented on NVO. Rothschild & Co Redburn upgraded shares of Novo Nordisk A/S from a “neutral” rating to a “buy” rating in a report on Tuesday, September 16th. HSBC reissued a “hold” rating and set a $54.00 price objective on shares of Novo Nordisk A/S in a research note on Wednesday, December 10th. Zacks Research downgraded shares of Novo Nordisk A/S from a “hold” rating to a “strong sell” rating in a research note on Wednesday, December 3rd. Argus reissued a “hold” rating on shares of Novo Nordisk A/S in a research report on Monday, December 8th. Finally, Berenberg Bank raised Novo Nordisk A/S from a “hold” rating to a “buy” rating in a research report on Wednesday, September 17th. One analyst has rated the stock with a Strong Buy rating, seven have assigned a Buy rating, eleven have assigned a Hold rating and four have assigned a Sell rating to the stock. Based on data from MarketBeat, Novo Nordisk A/S presently has a consensus rating of “Hold” and a consensus price target of $56.21.

Novo Nordisk A/S Trading Up 2.6%

Shares of NYSE NVO opened at $58.85 on Friday. The firm’s 50 day moving average price is $49.65 and its 200-day moving average price is $55.40. Novo Nordisk A/S has a 52-week low of $43.08 and a 52-week high of $93.80. The company has a debt-to-equity ratio of 0.52, a quick ratio of 0.57 and a current ratio of 0.78. The company has a market cap of $262.78 billion, a PE ratio of 17.11 and a beta of 0.66.

Novo Nordisk A/S (NYSE:NVO) last announced its quarterly earnings data on Wednesday, November 5th. The company reported $1.02 earnings per share for the quarter, topping analysts’ consensus estimates of $0.77 by $0.25. The company had revenue of $11.79 billion during the quarter, compared to analyst estimates of $11.98 billion. Novo Nordisk A/S had a net margin of 32.76% and a return on equity of 73.50%. On average, equities research analysts expect that Novo Nordisk A/S will post 3.84 EPS for the current fiscal year.

Novo Nordisk A/S Company Profile

Novo Nordisk A/S is a Danish multinational pharmaceutical company headquartered in Bagsværd, Denmark, best known for its leadership in diabetes care and metabolic health. The company traces its roots to early Danish insulin production in the 1920s and was established in its current form through a 1989 merger of predecessor companies. Novo Nordisk develops, manufactures and markets pharmaceutical products and devices that address chronic and serious diseases, with a strong emphasis on long-term treatment and patient support.

The company’s core product portfolio centers on diabetes therapies, including a range of insulins and modern incretin-based treatments.